Inhibitors of rotamase enzyme activity
AssigneesGPI NIL Holdings, Inc., The Johns Hopkins University School of Medicine
InventorsJoseph P. Steiner, Solomon Snyder, Gregory S. Hamilton, Ted Dawson
Life of this patent
Estimating the term…
Abstract
This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.
Claims10
A method of treating a neurological disorder in an animal, comprising:
- administering to the animal an effective amount of a immunosuppressive pipecolic acid derivative to treat a neurological disorder, wherein the immunosuppressive pipecolic acid derivative is not FK-506 or rapamycin.
A method of treating a neurological disorder in an animal, comprising:
- administering to the animal an effective amount of a immunosuppressive pipecolic acid derivative in combination with an effective amount of a neurotrophic factor selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, and neurotropin-3, to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the immunosuppressive pipecolic acid derivative is not FK-506 or rapamycin.
A method of treating Parkinson's disease, comprising:
- administering an effective neurotrophic amount of an immunosuprressive pipecolic acid derivative to a patient suffering from Parkinson's disease, wherein the immunosuppressive pipecolic acid derivative is not FK506 or rapamycin.
A method of treating Alzheimer's disease, comprising:
- administering an effective neurotrophic amount of an immunosuppressive pipecolic acid derivative to a patient suffering from Alzheimer's disease, wherein the immunosuppressive pipecolic acid derivative is not FK506 or rapamycin.
A method of treating neurodegenerative effects of amyotrophic lateral sclerosis, comprising:
- administering an effective neurotrophic amount of an immunosuppressive pipecolic acid derivative to a patient suffering from amyotrophic lateral sclerosis, wherein the immunosuppressive pipecolic acid derivative is not FK-506 or rapamycin.
A method of treating diabetic neuropathy, comprising:
- administering an effective neurotrophic amount of an immunosuppressive pipecolic acid derivative to a patient suffering from diabetic neuropathy, wherein the immunosuppressive pipecolic acid derivative is not FK-506 or rapamycin.
Dependencies are inferred from the claim text.